New York State Teachers Retirement System decreased its stake in Haemonetics Co. (NYSE:HAE) by 0.2% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 97,187 shares of the medical instruments supplier’s stock after selling 200 shares during the quarter. New York State Teachers Retirement System owned approximately 0.19% of Haemonetics worth $8,502,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently modified their holdings of the business. JPMorgan Chase & Co. increased its position in Haemonetics by 40.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 709,853 shares of the medical instruments supplier’s stock valued at $81,335,000 after acquiring an additional 203,656 shares in the last quarter. Vanguard Group Inc grew its position in shares of Haemonetics by 1.9% during the 3rd quarter. Vanguard Group Inc now owns 5,619,707 shares of the medical instruments supplier’s stock worth $643,906,000 after buying an additional 107,357 shares during the period. Bank of Montreal Can grew its position in shares of Haemonetics by 17.8% during the 4th quarter. Bank of Montreal Can now owns 2,052 shares of the medical instruments supplier’s stock worth $205,000 after buying an additional 310 shares during the period. Empowered Funds LLC acquired a new stake in shares of Haemonetics during the 4th quarter worth approximately $1,201,000. Finally, Assenagon Asset Management S.A. acquired a new stake in shares of Haemonetics during the 4th quarter worth approximately $1,137,000. Institutional investors and hedge funds own 98.91% of the company’s stock.
In related news, SVP Jacqueline Scanlan sold 1,508 shares of the business’s stock in a transaction on Tuesday, May 14th. The shares were sold at an average price of $100.00, for a total transaction of $150,800.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, VP Dan Goldstein sold 3,206 shares of the company’s stock in a transaction on Tuesday, April 9th. The shares were sold at an average price of $88.90, for a total transaction of $285,013.40. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 100,306 shares of company stock worth $9,720,660. 1.04% of the stock is owned by corporate insiders.
Several brokerages have recently commented on HAE. Raymond James upgraded shares of Haemonetics from a “market perform” rating to an “outperform” rating and set a $110.00 price target for the company in a research report on Tuesday, May 14th. TheStreet upgraded shares of Haemonetics from a “c+” rating to a “b-” rating in a research report on Tuesday, May 7th. Barrington Research reiterated an “outperform” rating and set a $116.00 price target (up previously from $112.00) on shares of Haemonetics in a research report on Wednesday, May 8th. Finally, Zacks Investment Research upgraded shares of Haemonetics from a “sell” rating to a “hold” rating in a research report on Tuesday, April 9th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Haemonetics has a consensus rating of “Buy” and an average price target of $118.60.
Haemonetics stock traded up $0.33 during midday trading on Friday, hitting $112.11. 412,305 shares of the stock were exchanged, compared to its average volume of 487,258. Haemonetics Co. has a 52 week low of $80.24 and a 52 week high of $117.56. The firm has a market capitalization of $5.64 billion, a price-to-earnings ratio of 46.91, a PEG ratio of 2.78 and a beta of 0.67. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.44 and a quick ratio of 1.62.
Haemonetics (NYSE:HAE) last released its quarterly earnings data on Tuesday, May 7th. The medical instruments supplier reported $0.61 earnings per share for the quarter, topping the consensus estimate of $0.55 by $0.06. The business had revenue of $249.30 million for the quarter, compared to analyst estimates of $250.62 million. Haemonetics had a net margin of 5.69% and a return on equity of 18.88%. Haemonetics’s quarterly revenue was up 6.7% compared to the same quarter last year. During the same quarter last year, the firm earned $0.43 EPS. As a group, analysts predict that Haemonetics Co. will post 2.93 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This story was published by Sundance Herald and is the property of of Sundance Herald. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright law. The original version of this story can be read at https://sundanceherald.com/2019/06/14/new-york-state-teachers-retirement-system-has-8-50-million-holdings-in-haemonetics-co-hae.html.
Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.
Featured Article: Fundamental Analysis – How It Helps Investors
Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.